Gilead Sciences, Inc. $GILD Stock Sold by Hennessy Advisors Inc.

Key Points

• Hennessy Advisors reduced its Gilead Sciences position by 21.6% in the third quarter, selling 18,399 shares and retaining 66,800 shares valued at approximately $10 million. Institutional investors collectively own 83.67% of the company.
• Gilead exceeded third-quarter expectations, reporting adjusted earnings of $2.55 per share and revenue of $8.30 billion, while raising its 2026 product-sales outlook to roughly $31.0 billion–$31.3 billion on strong HIV-treatment demand.
• Analyst sentiment is broadly positive, with 23 Buy ratings and six Holds and an average price target of $169.19. However, investors face longer-term risks from expected Medicare-driven pricing pressure on Biktarvy and the company’s reliance on its HIV portfolio.

Hennessy Advisors Inc. lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 21.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,800 shares of the biopharmaceutical company's stock after selling 18,399 shares during the period. Hennessy Advisors Inc.'s holdings in Gilead Sciences were worth $9,957,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at $15,393,785,000. State Street Corp lifted its holdings in Gilead Sciences by 2.3% during the second quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company's stock worth $7,734,099,000 after acquiring an additional 1,357,967 shares in the last quarter. Amundi lifted its holdings in Gilead Sciences by 10.7% during the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company's stock worth $1,468,836,000 after acquiring an additional 1,018,976 shares in the last quarter. Legal & General Group Plc acquired a new position in Gilead Sciences in the second quarter valued at about $1,316,606,000. Finally, Deutsche Bank AG acquired a new position in Gilead Sciences in the second quarter valued at about $918,387,000. Institutional investors own 83.67% of the company's stock.

Analyst Ratings Changes

GILD has been the subject of several recent analyst reports. Citigroup increased their price target on Gilead Sciences from $165.00 to $188.00 and gave the stock a "buy" rating in a report on Friday. Cantor Fitzgerald boosted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company an "overweight" rating in a research report on Friday. Morgan Stanley increased their target price on Gilead Sciences from $163.00 to $183.00 and gave the stock an "overweight" rating in a research note on Friday. Leerink Partners downgraded shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and dropped their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Finally, HSBC lifted their price target on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Twenty-three analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $169.19.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $170.68 on Monday. The company has a current ratio of 1.32, a quick ratio of 0.95 and a debt-to-equity ratio of 2.03. The business's 50 day moving average is $150.87 and its 200-day moving average is $139.79. Gilead Sciences, Inc. has a 1-year low of $114.02 and a 1-year high of $175.65. The firm has a market cap of $211.63 billion, a P/E ratio of -54.01 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating analysts' consensus estimates of $2.19 by $0.36. The company had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm's quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.47 earnings per share. Equities research analysts predict that Gilead Sciences, Inc. will post -1.03 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. Gilead Sciences's dividend payout ratio is -103.80%.

Insider Activity at Gilead Sciences

In related news, Director Anthony Welters sold 18,000 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the transaction, the director owned 12,894 shares of the company's stock, valued at $1,916,306.28. This represents a 58.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the transaction, the chief financial officer owned 161,096 shares of the company's stock, valued at $25,166,417.12. This represents a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 96,000 shares of company stock worth $13,923,210 in the last ninety days. Insiders own 0.30% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.